Publication:
Why Use Aprepitant Only as a Cough Suppressant in Lung Cancer When at Higher Doses it Could Also Exert an Antitumor Action?

dc.contributor.authorMuñoz, Miguel
dc.contributor.authorMuñoz, Miguel E
dc.contributor.authorMorell, Ferran
dc.contributor.authorCoveñas, Rafael
dc.date.accessioned2023-05-03T14:46:06Z
dc.date.available2023-05-03T14:46:06Z
dc.date.issued2022-05-13
dc.identifier.doi10.1016/j.arbres.2022.05.004
dc.identifier.essn1579-2129
dc.identifier.pmid35606264
dc.identifier.urihttp://hdl.handle.net/10668/22015
dc.issue.number10
dc.journal.titleArchivos de bronconeumologia
dc.journal.titleabbreviationArch Bronconeumol
dc.language.isoen
dc.language.isoes
dc.organizationEmpresa Pública de Emergencias Sanitarias-EPES
dc.organizationHospital Universitario Virgen del Rocío
dc.organizationInstituto de Biomedicina de Sevilla-IBIS
dc.page.number727-728
dc.pubmedtypeLetter
dc.subject.meshAntitussive Agents
dc.subject.meshAprepitant
dc.subject.meshHumans
dc.subject.meshLung Neoplasms
dc.titleWhy Use Aprepitant Only as a Cough Suppressant in Lung Cancer When at Higher Doses it Could Also Exert an Antitumor Action?
dc.typeresearch article
dc.volume.number58
dspace.entity.typePublication

Files